ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer

被引：23
作者：
Bolger, Jarlath C. [1 ]
Young, Leonie S. [1 ]
机构：
[1] Royal Coll Surgeons Ireland, Dublin 2, Ireland
来源：
HORMONES AND BREAST CANCER | 2013年 / 93卷
关键词：
METALLOPROTEASE-DISINTEGRIN; MATRIX METALLOPROTEINASES; IN-VITRO; EXPRESSION; LGI1; INHIBITION; DOMAIN; INVASION; ISOFORMS; RECEPTOR;
D O I：
10.1016/B978-0-12-416673-8.00014-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The development of breast cancer resistance to endocrine therapies may result from an increase in cellular plasticity, permitting the emergence of a hormone-independent tumor. ADAM proteins are multidomain transmembrane proteins that have a diverse array of functions in both natural physiology and disease. A number of ADAM proteins have been implicated in the occurrence of breast cancer, including ADAM 9, ADAM12, ADAM15, ADAM17, ADAM22, and ADAM28. ADAM22 expression is driven by the coactivator protein SRC-1 in response to tamoxifen treatment in the resistant setting. ADAM22 is an ER-independent predictor of disease-free survival. LGI1 is a neuropeptide that binds ADAM22 in the nervous system. In addition to being a ligand for ADAM11, ADAM22, and ADAM23, LGI1 may play a role as a tumor suppressor. Furthermore, LGI1 may act to reduce cell migration and may impair proliferation. Therapies based on LGI1 may provide a building block for future therapies in ADAM22-positive breast cancer.
引用
收藏
页码：307 / 321
页数：15
相关论文
共 41 条
[1]   A POTENTIAL FUSION PEPTIDE AND AN INTEGRIN LIGAND DOMAIN IN A PROTEIN ACTIVE IN SPERM-EGG FUSION [J].
BLOBEL, CP ;
WOLFSBERG, TG ;
TURCK, CW ;
MYLES, DG ;
PRIMAKOFF, P ;
WHITE, JM .
NATURE, 1992, 356 (6366) :248-252
[2]   INHIBITION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY BY ASSOCIATION WITH 14-3-3-PROTEINS IN T-CELLS [J].
BONNEFOYBERARD, N ;
LIU, YC ;
VONWILLEBRAND, M ;
SUNG, A ;
ELLY, C ;
MUSTELIN, T ;
YOSHIDA, H ;
ISHIZAKA, K ;
ALTMAN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (22) :10142-10146
[3]   Metalloprotease-disintegrin ADAM 12 interacts with α-actinin-1 [J].
Cao, Y ;
Kang, Q ;
Zolkiewska, A .
BIOCHEMICAL JOURNAL, 2001, 357 :353-361
[4]   TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells [J].
Cesi, Vincenzo ;
Casciati, Arianna ;
Sesti, Fabiola ;
Tanno, Barbara ;
Calabretta, Bruno ;
Raschella, Giuseppe .
CELL CYCLE, 2011, 10 (23) :4149-4161
[5]   Part-time α-secretases:: The functional biology of ADAM 9, 10 and 17 [J].
Deuss, Miriam ;
Reiss, Karina ;
Hartmann, Dieter .
CURRENT ALZHEIMER RESEARCH, 2008, 5 (02) :187-201
[6]   The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer? [J].
Duffy M.J. ;
Mullooly M. ;
O'Donovan N. ;
Sukor S. ;
Crown J. ;
Pierce A. ;
McGowan P.M. .
Clinical Proteomics, 2011, 8 (1)
[7]   Proteolytic processing of Delta-like 1 by ADAM proteases [J].
Dyczynska, Emilia ;
Sun, Danqiong ;
Yi, Haiqing ;
Sehara-Fujisawa, Atsuko ;
Blobel, Carl P. ;
Zolkiewska, Anna .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (01) :436-444
[8]   The ADAM metalloproteinases [J].
Edwards, Dylan R. ;
Handsley, Madeleine M. ;
Pennington, Caroline J. .
MOLECULAR ASPECTS OF MEDICINE, 2008, 29 (05) :258-289
[9]   14-3-3 proteins interact with specific MEK kinases [J].
Fanger, GR ;
Widmann, C ;
Porter, AC ;
Sather, S ;
Johnson, GL ;
Vaillancourt, RR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3476-3483
[10]   Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer [J].
Fridman, Jordan S. ;
Caulder, Eian ;
Hansbury, Michael ;
Liu, Xiangdong ;
Yang, Genjie ;
Wang, Qian ;
Lo, Yvonne ;
Zhou, Bin-Bing ;
Pan, Maxwell ;
Thomas, Sufi M. ;
Grandis, Jennifer R. ;
Zhuo, Jincong ;
Yao, Wenqing ;
Newton, Robert C. ;
Friedman, Steven M. ;
Scherle, Peggy A. ;
Vaddi, Kris .
CLINICAL CANCER RESEARCH, 2007, 13 (06) :1892-1902
12345